The BTK inhibitor ibrutinib and the BCL-2 antagonist venetoclax are routinely used in practice for the treatment of relapsed/refractory MCL and are increasingly used in newly diagnosed MCL in clinical trials. Here, BTK is linked to mantle cell lymphoma.